These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38054608)

  • 1. Variables predicting clinical remission among adults with severe asthma treated with biologic agents.
    Yeşilkaya S; Aksu K; Tuğçe Vural Solak G; Akkale O; Telli O; Tuğlu HC; Köycü Buhari G; Bahçecioğlu SN; Demir S
    Eur Ann Allergy Clin Immunol; 2024 Sep; 56(5):219-226. PubMed ID: 38054608
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
    Nopsopon T; Barrett NA; Phipatanakul W; Laidlaw TM; Weiss ST; Akenroye A
    Allergy; 2024 May; 79(5):1195-1207. PubMed ID: 38164813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.
    Thomas D; McDonald VM; Stevens S; Harvey ES; Baraket M; Bardin P; Bowden JJ; Bowler S; Chien J; Chung LP; Gillman A; Hew M; Hodge S; James A; Jenkins C; Katelaris CH; Katsoulotos GP; Langton D; Lee J; Marks G; Peters M; Radhakrishna N; Reynolds PN; Rimmer J; Sivakumaran P; Upham JW; Wark P; Yang IA; Gibson PG
    Allergy; 2024 Feb; 79(2):384-392. PubMed ID: 37632144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.
    Lim YT; Williams TC; Langley RJ; Weir E
    J Asthma; 2024 Aug; 61(8):793-800. PubMed ID: 38240489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
    Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
    Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phenotypic heterogeneity of obese and nonobese patients with severe asthma and comparison of omalizumab-mepolizumab treatment efficiency in these patients.
    Özden Ş; Tepetam FM; Örçen C; Yakut T
    Medicine (Baltimore); 2023 Oct; 102(43):e35247. PubMed ID: 37904405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
    Valverde-Monge M; Sánchez-Carrasco P; Betancor D; Barroso B; Rodrigo-Muñoz JM; Mahillo-Fernández I; Arismendi E; Bobolea I; Cárdaba B; Cruz MJ; Del Pozo V; Domínguez-Ortega J; González-Barcala FJ; Olaguibel JM; Luna-Porta JA; Martínez-Rivera C; Mullol J; Muñoz X; Peleteiro-Pedraza L; Picado Valles C; Plaza V; Quirce S; Rial MJ; Soto-Retes L; Valero A; Sastre J
    Arch Bronconeumol; 2024 Jan; 60(1):23-32. PubMed ID: 38042707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
    Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö
    Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO
    Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial.
    Cornelius V; Babalis D; Carroll WD; Cunningham S; Fleming L; Gaillard E; Gupta A; Janani L; Kennington E; Murray C; Nagakumar P; Roberts G; Seddon P; Sinha I; Streatfield C; Weir E; Saglani S
    BMJ Open; 2024 Aug; 14(8):e090749. PubMed ID: 39174059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.
    Casale TB; Chipps BE; Rosén K; Trzaskoma B; Haselkorn T; Omachi TA; Greenberg S; Hanania NA
    Allergy; 2018 Feb; 73(2):490-497. PubMed ID: 28859263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.
    Sposato B; Scalese M; Latorre M; Scichilone N; Matucci A; Milanese M; Masieri S; Rolla G; Steinhilber G; Rosati Y; Vultaggio A; Folletti I; Baglioni S; Bargagli E; Di Tomassi M; Pio R; Pio A; Maccari U; Maggiorelli C; Migliorini MG; Vignale L; Pulerà N; Carpagnano GE; Foschino Barbaro MP; Perrella A; Paggiaro PL
    Respir Med; 2016 Oct; 119():141-149. PubMed ID: 27692136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.
    Perez-de-Llano L; Scelo G; Tran TN; Le TT; Fagerås M; Cosio BG; Peters M; Pfeffer PE; Al-Ahmad M; Al-Lehebi RO; Altraja A; Bergeron C; Bjermer LH; Bjerrum AS; Bulathsinhala L; Busby J; Cano Rosales DJ; Canonica GW; Carter VA; Charriot J; Christoff GC; Denton EJ; Dorscheid DR; Fernandez Sanchez MJ; Fonseca JA; Gibson PG; Goh CYY; Heaney LG; Heffler E; Hew M; Iwanaga T; Katial R; Koh MS; Kuna P; Larenas-Linnemann DES; Lehtimäki L; Mahboub B; Martin N; Matsumoto H; Menzies-Gow AN; Papadopoulos NG; Popov TA; Porsbjerg CM; Patel P; Rhee CK; Sadatsafavi M; Taillé C; Torres-Duque CA; Tsai MJ; Ulrik CS; Upham JW; von Bülow A; Wang E; Wechsler ME; Price DB
    Am J Respir Crit Care Med; 2024 Oct; 210(7):869-880. PubMed ID: 38701495
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
    Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.